NCT04075110View on ClinicalTrials.gov

Investigation the Safety and Efficacy of The Antileukotriene Agents, Montelukast, as Adjuvant Therapy in Obese Patients With Type 2 Diabetes Mellitus

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 1, 2019

Primary Completion Date

June 1, 2022

Study Completion Date

April 10, 2023

Conditions
Obesity; Endocrine; Diabetes Type 2
Interventions
DRUG

Montelukast 10mg

Montelukast is an orally dosed drug (available as a chewable tablet) which is FDA-approved for the treatment of chronic asthma and prophylaxis and the prevention of exercise-induced bronchoconstriction. It is also approved for the relief of symptoms of both seasonal and perennial allergic rhinitis.

DRUG

Placebo

Placebo tablet once daily

Trial Locations (1)

Unknown

Faculty of Medicine, Shebin Elkom

All Listed Sponsors
lead

Sadat City University

OTHER

NCT04075110 - Investigation the Safety and Efficacy of The Antileukotriene Agents, Montelukast, as Adjuvant Therapy in Obese Patients With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter